# èƒ°è…ºç™Œä¸´åºŠè¯•éªŒæŠ¥å‘Š

**ç”Ÿæˆæ—¥æœŸ**: 2025-06-07
**æŸ¥è¯¢æ¡ä»¶**: èƒ°è…ºç™Œç›¸å…³çš„æ´»è·ƒä¸´åºŠè¯•éªŒ
**æŸ¥è¯¢èŒƒå›´**: æœ€è¿‘30å¤©å†…æ–°å¢æˆ–æ›´æ–°çš„è¯•éªŒ
**è¯•éªŒæ€»æ•°**: 11
**æ™ºèƒ½ç¿»è¯‘**: âœ… å·²å¯ç”¨

> ğŸ“ **è¯´æ˜**: æœ¬æŠ¥å‘Šæä¾›ä¸­è‹±æ–‡å¯¹ç…§ä¿¡æ¯ï¼Œå…³é”®åŒ»å­¦æœ¯è¯­ä¿æŒåŸæ–‡ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚

## è¯•éªŒåˆ—è¡¨

### æ­£åœ¨æ‹›å‹Ÿçš„è¯•éªŒ

## ä¸€é¡¹é’ˆå¯¹PARP1é€‰æ‹©æ€§æŠ‘åˆ¶å‰‚EIK1004ï¼ˆIMP1707ï¼‰åœ¨æ™šæœŸå®ä½“è‚¿ç˜¤æ‚£è€…ä¸­çš„ç ”ç©¶ã€‚ (A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.)

**è¯•éªŒç¼–å·**: NCT06907043  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹1/2æœŸã€å¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒã€å‰‚é‡é€’å¢åŠä¼˜åŒ–ç ”ç©¶ï¼Œæ—¨åœ¨è¯„ä¼°EIK1004ï¼ˆIMP1707ï¼‰ä½œä¸ºå•è¯æ²»ç–—åœ¨æ™šæœŸå®ä½“ç˜¤æ‚£è€…ä¸­çš„å®‰å…¨æ€§ã€è€å—æ€§åŠæ´»æ€§ã€‚ (A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors)  
**ç–¾ç—…æ¡ä»¶**: æ™šæœŸå®ä½“è‚¿ç˜¤ (Advanced Solid Tumors)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE1, PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: EIK1004-001ï¼ˆIMP1707-001ï¼‰ (EIK1004-001 (IMP1707-001))  
**å¹²é¢„ç±»å‹**: DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Eikon Therapeutics  
**è¯•éªŒåœ°ç‚¹**: MD Anderson, Houston, United States; Fudan University Shanghai Cancer Center, Shanghai, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 130  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-03-22  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Sunny Chaudry, MS  
**ç”µè¯**: 6319026200  
**é‚®ç®±**: chaudrys@eikontx.com  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06907043)

---

## ä¸€é¡¹é’ˆå¯¹æºå¸¦KRAS G12Vçªå˜æ™šæœŸèƒ°è…ºç™Œæ‚£è€…çš„IX001 TCR-Tæ³¨å°„å‰‚IæœŸä¸´åºŠè¯•éªŒç ”ç©¶ã€‚ (A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation)

**è¯•éªŒç¼–å·**: NCT06898385  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹é’ˆå¯¹æºå¸¦KRAS G12Vçªå˜æ™šæœŸèƒ°è…ºç™Œæ‚£è€…çš„IX001 TCR-Tæ³¨å°„å‰‚IæœŸä¸´åºŠè¯•éªŒç ”ç©¶ã€‚ (A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation)  
**ç–¾ç—…æ¡ä»¶**: èƒ°è…ºç™Œ (Pancreatic Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE1  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: IX001 Tç»†èƒå—ä½“-Tç»†èƒæ³¨å°„ï¼Œæ°Ÿè¾¾æ‹‰æ»¨ï¼Œç¯ç£·é…°èƒºæ²»ç–—ã€‚ (IX001 TCR-T injection, Fludarabine, Cyclophosphamide)  
**å¹²é¢„ç±»å‹**: ç”Ÿç‰©åˆ¶å‰‚ã€è¯ç‰©ã€è¯ç‰©ã€‚ (BIOLOGICAL, DRUG, DRUG)  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Sun Yat-sen University  
**è¯•éªŒåœ°ç‚¹**: Sun Yat-sen University Cancer Center, Guangzhou, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 9  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-03-21  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Yuhong Li  
**ç”µè¯**: 87342487  
**é‚®ç®±**: liyh@sysucc.org.cn  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06898385)

---

## ä¸€é¡¹ç ”ç©¶ï¼Œæ—¨åœ¨äº†è§£BAY2927088ç‰‡æ²»ç–—åœ¨æºå¸¦äººç±»è¡¨çš®ç”Ÿé•¿å› å­å—ä½“2ï¼ˆHER2ï¼‰çªå˜çš„æœ‰å®ä½“è‚¿ç˜¤å‚ä¸è€…ä¸­çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚ (A Study to Learn More About How Well Treatment With BAY2927088 Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2))

**è¯•éªŒç¼–å·**: NCT06760819  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹å¼€æ”¾å¼æ ‡ç­¾çš„äºŒæœŸç¯®å¼ç ”ç©¶ï¼Œæ—¨åœ¨è¯„ä¼°å£æœå¯é€†æ€§é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚BAY 2927088åœ¨æºå¸¦HER2æ¿€æ´»çªå˜çš„è½¬ç§»æ€§æˆ–ä¸å¯åˆ‡é™¤å®ä½“ç˜¤æ‚£è€…ä¸­çš„ç–—æ•ˆä¸å®‰å…¨æ€§ã€‚ (A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations)  
**ç–¾ç—…æ¡ä»¶**: æ™šæœŸå®ä½“è‚¿ç˜¤ï¼ŒHER2çªå˜ (Advanced Solid Tumors, HER2 Mutation)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: BAY2927088  
**å¹²é¢„ç±»å‹**: DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Bayer  
**è¯•éªŒåœ°ç‚¹**: University of Alabama at Birmingham, Birmingham, United States; City of Hope - Duarte Cancer Center, Duarte, United States; Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers, United States  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 111  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2024-12-18  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Bayer Clinical Trials Contact  
**ç”µè¯**: (+)1-888-84 22937  
**é‚®ç®±**: clinical-trials-contact@bayer.com  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760819)

---

## ä¸€é¡¹å…³äºIvonescimabè”åˆåŒ–ç–—ä½œä¸ºä¸´ç•Œå¯åˆ‡é™¤èƒ°è…ºç™Œæ–°è¾…åŠ©æ²»ç–—çš„ç ”ç©¶ã€‚ (A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer)

**è¯•éªŒç¼–å·**: NCT06944106  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹å‰ç»æ€§ã€å•è‡‚ã€IIæœŸä¸´åºŠè¯•éªŒï¼Œè¯„ä¼°Ivonescimabè”åˆå‰è¥¿ä»–æ»¨å’Œé˜¿æ¯”ç‰¹é¾™ï¼ˆAGï¼‰æ–¹æ¡ˆä½œä¸ºä¸´ç•Œå¯åˆ‡é™¤èƒ°è…ºç™Œæ–°è¾…åŠ©æ²»ç–—çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚ (A Prospective, Single-arm, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab Combined With Gemcitabine and Nab-paclitaxel (AG) Regimen as Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer)  
**ç–¾ç—…æ¡ä»¶**: èƒ°è…ºç™Œ (Pancreatic Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: AK112  
**å¹²é¢„ç±»å‹**: DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Tianjin Medical University Cancer Institute and Hospital  
**è¯•éªŒåœ°ç‚¹**: Tianjin Cancer Hospital Airport Hospital, Tianjin, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 30  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-04-17  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Li Huikai, MD  
**ç”µè¯**: 18622228639  
**é‚®ç®±**: tjchlhk@126.com  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06944106)

---

## é€‚åº”æ€§å¼•å¯¼ç«‹ä½“å®šå‘ä½“éƒ¨æ”¾ç–—è”åˆåŒ–ç–—åŠæ–°å‹è¯ç‰©Ivonescimabæ²»ç–—èƒ°è…ºç™Œï¼ˆASCENDï¼‰ç ”ç©¶è®¡åˆ’ã€‚ (Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND))

**è¯•éªŒç¼–å·**: NCT06844422  
**æ­£å¼æ ‡é¢˜**: é€‚åº”æ€§å¼•å¯¼ç«‹ä½“å®šå‘ä½“éƒ¨æ”¾ç–—è”åˆåŒ–ç–—åŠæ–°å‹è¯ç‰©Ivonescimabæ²»ç–—èƒ°è…ºç™Œï¼ˆASCENDï¼‰- å•è‡‚ Ib/IIæœŸä¸´åºŠè¯•éªŒ (Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) -A Single-Arm Phase Ib/II Trial)  
**ç–¾ç—…æ¡ä»¶**: èƒ°è…ºç™Œ (Pancreatic Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE1, PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: ä¼Šæ²ƒå°¼å•æŠ— (Ivonescimab)  
**å¹²é¢„ç±»å‹**: DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Shandong Cancer Hospital and Institute  
**è¯•éªŒåœ°ç‚¹**: Shandong Cancer Hospital and Institute, Jinan, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 37  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-02-19  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Jinbo Yue, Doctor  
**ç”µè¯**: 0531-67626442  
**é‚®ç®±**: jbyue@sdfmu.edu.cn  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06844422)

---

## CAR-NKç»†èƒï¼ˆCL-NK-001ï¼‰åœ¨èƒ°è…ºç™Œä¸­çš„è¿ç”¨ (CAR-NK Cells (CL-NK-001) in Pancreatic Cancer)

**è¯•éªŒç¼–å·**: NCT06816823  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹é’ˆå¯¹æ™šæœŸèƒ°è…ºç™Œæ‚£è€…ä½¿ç”¨CAR-NKç»†èƒï¼ˆCL-NK-001ï¼‰çš„ä¸´åºŠç ”ç©¶ (A Clinical Study of CAR-NK Cells (CL-NK-001) in Patients With Advanced Pancreatic Cancer)  
**ç–¾ç—…æ¡ä»¶**: èƒ°è…ºç™Œ (Pancreatic Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE1  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: CL-NK-001æ˜¯ä¸€ç§è¯ç‰©çš„ä»£å·ã€‚ (CL-NK-001)  
**å¹²é¢„ç±»å‹**: ç”Ÿç‰©åˆ¶å“ (BIOLOGICAL)  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Changhai Hospital  
**è¯•éªŒåœ°ç‚¹**: Changhai Hospital, Shanghai, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 30  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-02-01  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Yanfang Liu, MD PhD  
**ç”µè¯**: +86-13124828854  
**é‚®ç®±**: liuyanfang00215@163.com  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06816823)

---

## å¯¹æ™šæœŸå®ä½“è‚¿ç˜¤æ‚£è€…è¿›è¡Œçš„AZD4360ç ”ç©¶ã€‚ (Study for AZD4360 in Participants With Advanced Solid Tumours)

**è¯•éªŒç¼–å·**: NCT06921928  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹I/IIæœŸå¼€æ”¾æ ‡ç­¾å‰‚é‡é€’å¢å’Œæ‰©å±•ç ”ç©¶ï¼Œè¯„ä¼°AZD4360åœ¨æ‚£æœ‰æ™šæœŸå®ä½“ç˜¤æˆäººå‚ä¸è€…ä¸­çš„å®‰å…¨æ€§ã€è¯ä»£åŠ¨åŠ›å­¦ã€è¯æ•ˆå­¦å’Œç–—æ•ˆã€‚ (A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours)  
**ç–¾ç—…æ¡ä»¶**: èƒƒç™Œã€èƒƒé£Ÿç®¡äº¤ç•Œç™Œã€èƒ†é“ç™Œã€èƒ°è…ºå¯¼ç®¡è…ºç™Œ (Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE1, PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: AZD4360  
**å¹²é¢„ç±»å‹**: DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: AstraZeneca  
**è¯•éªŒåœ°ç‚¹**: Research Site, Los Angeles, United States; Research Site, Providence, United States; Research Site, Houston, United States  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 117  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-03-25  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: AstraZeneca Clinical Study Information Center  
**ç”µè¯**: 1-877-240-9479  
**é‚®ç®±**: information.center@astrazeneca.com  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06921928)

---

## ä»–è«æ˜”èŠ¬ç”¨äºæ²»ç–—èƒ°è…ºå®æ€§å‡ä¹³å¤´çŠ¶è‚¿ç˜¤æ™šæœŸç—…ä¾‹ (Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas)

**è¯•éªŒç¼–å·**: NCT06914674  
**æ­£å¼æ ‡é¢˜**: ä»–è«æ˜”èŠ¬ç”¨äºæ²»ç–—èƒ°è…ºå®æ€§å‡ä¹³å¤´çŠ¶è‚¿ç˜¤æ™šæœŸç—…ä¾‹ (Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas)  
**ç–¾ç—…æ¡ä»¶**: èƒ°è…ºè‚¿ç˜¤ (Pancreatic Neoplasms)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: ä»–è«æ˜”èŠ¬ 20 æ¯«å…‹ (Tamoxifen 20 mg)  
**å¹²é¢„ç±»å‹**: DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Fudan University  
**è¯•éªŒåœ°ç‚¹**: Shanghai Cancer Center, Shanghai, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 30  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-03-31  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Huanyu Xia MD  
**ç”µè¯**: 86 21 64031446  
**é‚®ç®±**: xiahuanyu@fudanpci.org  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914674)

---

## è…¹è†œè½¬ç§»æ€§èƒ°è…ºç™Œæ‚£è€…è…¹è…”çƒ­çŒæ³¨åŒ–ç–—è”åˆé™è„‰åŒ–ç–—çš„å®‰å…¨æ€§åŠæœ‰æ•ˆæ€§ï¼šIIæœŸä¸´åºŠè¯•éªŒ (The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial)

**è¯•éªŒç¼–å·**: NCT06946901  
**æ­£å¼æ ‡é¢˜**: è…¹è†œè½¬ç§»æ€§èƒ°è…ºç™Œæ‚£è€…è…¹è…”çƒ­çŒæ³¨åŒ–ç–—è”åˆé™è„‰åŒ–ç–—çš„å®‰å…¨æ€§åŠæœ‰æ•ˆæ€§ï¼šIIæœŸä¸´åºŠè¯•éªŒ (The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial)  
**ç–¾ç—…æ¡ä»¶**: è…¹è…”çƒ­çŒæ³¨åŒ–ç–—ï¼Œè…¹è†œè½¬ç§»æ€§èƒ°è…ºç™Œæ²»ç–—ã€‚ (Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Metastatic Pancreatic Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: è…¹è…”é«˜æ¸©åŒ–ç–—ï¼ˆHIPECï¼‰è”åˆé¡ºé“‚ + å…¨èº«AGåŒ–ç–—æ–¹æ¡ˆã€‚ (Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy)  
**å¹²é¢„ç±»å‹**: COMBINATION_PRODUCT  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Shanghai Zhongshan Hospital  
**è¯•éªŒåœ°ç‚¹**: The Second Xiangya Hospital of Central South University, Changsha, China; Zhongshan Hospital, Fudan University, Shanghai, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 90  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-04-19  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Wenquan Wang, Dr  
**ç”µè¯**: 86 13701874954  
**é‚®ç®±**: wang.wenquan@zs-hospital.sh.cn  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06946901)

---

## ç™½è›‹ç™½ç»“åˆå‹ç´«æ‰é†‡ä¸å‰è¥¿ä»–æ»¨è”åˆæˆ–ä¸è”åˆS-1ä½œä¸ºæ™šæœŸèƒ°è…ºç™Œçš„ä¸€çº¿æ²»ç–—ã€‚ (Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer)

**è¯•éªŒç¼–å·**: NCT06789679  
**æ­£å¼æ ‡é¢˜**: éšæœºäºŒæœŸä¸´åºŠç ”ç©¶ï¼šä»¥ç™½è›‹ç™½ç»“åˆå‹ç´«æ‰é†‡å’Œå‰è¥¿ä»–æ»¨ï¼Œè”åˆæˆ–ä¸è”åˆS-1ä½œä¸ºå±€éƒ¨æ™šæœŸæˆ–è½¬ç§»æ€§èƒ°è…ºç™Œä¸€çº¿æ²»ç–—çš„æ¯”è¾ƒç ”ç©¶ã€‚ (Randomized Phase II Clinical Study of Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer)  
**ç–¾ç—…æ¡ä»¶**: èƒ°è…ºè…ºç™Œ (Pancreatic Adenocarcinoma)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: å‰è¥¿ä»–æ»¨ã€ç™½è›‹ç™½ç»“åˆå‹ç´«æ‰é†‡ã€S-1ã€å‰è¥¿ä»–æ»¨ã€ç™½è›‹ç™½ç»“åˆå‹ç´«æ‰é†‡ã€‚ (Gemcitabine, albumin-bound paclitaxel, S-1, Gemcitabine, albumin-bound paclitaxel)  
**å¹²é¢„ç±»å‹**: DRUG, DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Cancer Institute and Hospital, Chinese Academy of Medical Sciences  
**è¯•éªŒåœ°ç‚¹**: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 128  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-01-17  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Lin Yang, Doctor  
**ç”µè¯**: 13681015148  
**é‚®ç®±**: linyangcicams@126.com  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06789679)

---

## ä¸€é¡¹å…³äºTQB2916æ³¨å°„å‰‚è”åˆç›é…¸å‰è¥¿ä»–æ»¨æ³¨å°„å‰‚å’Œç™½è›‹ç™½ç»“åˆå‹æ³¨å°„ç”¨ç´«æ‰é†‡ä¸€çº¿æ²»ç–—è½¬ç§»æ€§èƒ°è…ºç™Œçš„ä¸´åºŠç ”ç©¶ (A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type))

**è¯•éªŒç¼–å·**: NCT06962267  
**æ­£å¼æ ‡é¢˜**: ä¸€é¡¹IIæœŸä¸´åºŠè¯•éªŒï¼Œè¯„ä¼°TQB2916æ³¨å°„å‰‚è”åˆå‰è¥¿ä»–æ»¨å’Œç™½è›‹ç™½ç´«æ‰é†‡ä½œä¸ºè½¬ç§»æ€§èƒ°è…ºç™Œä¸€çº¿æ²»ç–—çš„ç–—æ•ˆä¸å®‰å…¨æ€§ã€‚ (A Phase II Clinical Study to Evaluate the Efficacy and Safety of TQB2916 Injection Combined With Gemcitabine and Albumin-paclitaxel as First-line Treatment for Metastatic Pancreatic Cance)  
**ç–¾ç—…æ¡ä»¶**: èƒ°è…ºç™Œ (Pancreatic Cancer)  
**è¯•éªŒçŠ¶æ€**: RECRUITING  
**è¯•éªŒé˜¶æ®µ**: PHASE2  
**ç ”ç©¶ç±»å‹**: INTERVENTIONAL  

### å¹²é¢„æªæ–½
**å¹²é¢„åç§°**: æ³¨å°„ç”¨TQB2916ï¼ŒåŒ–ç–— (TQB2916 Injection, Chemotherapy)  
**å¹²é¢„ç±»å‹**: DRUG, DRUG  

### è¯•éªŒä¿¡æ¯
**ä¸»è¦å‘èµ·æ–¹**: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.  
**è¯•éªŒåœ°ç‚¹**: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China  
**å¼€å§‹æ—¥æœŸ**: N/A  
**é¢„è®¡å®Œæˆæ—¥æœŸ**: N/A  
**æ‹›å‹Ÿäººæ•°**: 50  

### é‡è¦æ—¥æœŸ
**é¦–æ¬¡æäº¤**: 2025-04-30  
**æœ€åæ›´æ–°**: N/A  

### è”ç³»ä¿¡æ¯
**è”ç³»äºº**: Yi Ba, Doctor  
**ç”µè¯**: 13752157916  
**é‚®ç®±**: Bayi@tjmuch.com  

**è¯•éªŒé“¾æ¥**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06962267)

---

